<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036671</url>
  </required_header>
  <id_info>
    <org_study_id>VAP-0001</org_study_id>
    <nct_id>NCT02036671</nct_id>
  </id_info>
  <brief_title>Novel Endovascular Access Trial (NEAT)</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Novel Endovascular Access Trial (NEAT): A Study of the FLEX System for Percutaneous AV Fistula Creation in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TVA Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TVA Medical Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of the FLEX System when
      used to create an arteriovenous fistula (AVF or AV fistula) percutaneously in patients with
      Chronic Kidney Disease (CKD) who require hemodialysis vascular access.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12 month multi-center non-randomized investigational study to evaluate the safety
      and efficacy of the FLEX system to create an endovascular AVF in patients with CKD who
      require hemodialysis vascular access.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint:</measure>
    <time_frame>within 3 months</time_frame>
    <description>The percentage of patients with fistula maturation/usability defined as endoAVF that is free of stenosis or thrombosis, with brachial artery flow of at least 500 ml/min and at least 4 mm vein diameter (as measured by duplex ultrasound) OR patient was dialyzed using 2 needles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint</measure>
    <time_frame>within 3 months</time_frame>
    <description>The percentage of patients who experience one or more serious study device related adverse events during the first 3 months following AVF creation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EndoAVF-related Re-intervention Rate</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>The re-intervention rate for endoAVF (defined as any intervention required to maintain or re-establish patency) will be calculated at 3, 6 and 12 months post index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Time from successful endoAVF creation to the first intervention designed to address thrombosis or stenosis, assist in maturation or cannulation of endoAVF, or endoAVF abandonment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Patency</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Time from creation to the abandonment of endoAVF (censor patients with renal transplant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Usability</measure>
    <time_frame>4 weeks post procedure, up to 12 months</time_frame>
    <description>2-needle cannulation of the endoAVF for prescribed dialysis in â‰¥ 2/3 of dialysis sessions over a 4 consecutive week period within 12 months of endoAVF creation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>EndoAVF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access</intervention_name>
    <arm_group_label>EndoAVF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for a native surgical arteriovenous fistula, as determined by the treating
             physician.

          -  Adult (age &gt;18 years old).

          -  Established, non-reversible kidney failure requiring hemodialysis.

          -  Written informed consent obtained.

        Exclusion Criteria:

          -  Functioning surgical access in the planned treatment arm.

          -  Pregnant women.

          -  New York Heart Association (NYHA) class III or IV heart failure.

          -  Allergy to contrast dye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charmaine Lok, MD, MSC, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Toronto General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dheeraj Rajan, MD, BSc, FRCPC, FSIR</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Toronto General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QE II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM, Notre-Dame Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arteriovenous fistula</keyword>
  <keyword>Fistula</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Percutaneous</keyword>
  <keyword>Kidney Disease</keyword>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>CKD</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

